💊💉 #avelumab SmPC for Bavencio 20 mg/mL concentrate for solution for infusion has been updated with changes to sections 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 6.1 List of excipients; 6.3 Shelf life; 6.6 Special precautions for disposal; Revised: 09/2024. 🌐 https://www.medicines.org.uk/emc/product/8453/smpc Change log: https://www.medicines.org.uk/emc/product/8453/smpc/history

💊💉 #avelumab
SmPC for Bavencio 20 mg/mL concentrate for solution for infusion has been updated with changes to sections 3. Pharmaceutical form; 4.2 Posology and method of administration; 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 5.2 Pharmacokinetic properties; 6.3 Shelf life; 6.4 Special precautions for storage; 10. Date of revision of the text on 06/2024.
🌐 https://www.medicines.org.uk/emc/product/8453/smpc
Change log: https://www.medicines.org.uk/emc/product/8453/smpc/history

💊💉 #avelumab
SmPC for Bavencio 20 mg/mL concentrate for solution for infusion has been updated with changes to sections 4.4 Special warnings and precautions for use; 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 5.2 Pharmacokinetic properties; 10. Date of revision of the text on 01/2024.
🌐 https://www.medicines.org.uk/emc/product/8453/smpc
Change log: https://www.medicines.org.uk/emc/product/8453/smpc/history

Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons